Phase III randomized, multicentre, open, parallel group trial to compare the efficacy and tolerability of fulvestrant (Faslodex®) for three years in combination with anastrazole (Arimidex®) for 5 years versus anastrazole for 5 years as adjuvant hormone treatment in postmenopausal women with early breast cancer and positive hormone receptors.
Grupo Español de Investigación en Cáncer de Mama
Pathology and candidate patients
Early breast cancer Women with early breast cancer and positive hormone receptors.
Dr. Joseba Rebollo Liceaga
Plataforma Oncología. Hospital Quirónsalud Torrevieja.
Active. Start date 29/01/2008
Fulvestrant y Anastrazol
Hospital Quirónsalud Torrevieja (antiguo USP Hospital San Jaime)
If you are interested in this clinical trial because you believe that you or a family member of yours can benefit from this new treatment. You can request a consultation with the responsible specialist in our center [Dr. Joseba Rebollo Liceaga] by sending an email to the address: email@example.com